Literature DB >> 7750086

Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones.

L A Hazlehurst1, A P Krapcho, M P Hacker.   

Abstract

Doxorubicin and mitoxantrone are carboxyclic anti-cancer drugs that interact with DNA through intercalation. Our laboratory has synthesized a new series of anti-tumor agents, the aza-anthracenediones, which are structurally related to mitoxantrone but contain a heterocyclic, rather than a carbocyclic, chromophore. Both the in vivo and in vitro anti-tumor activities of these compounds were exquisitely sensitive to the positioning of the nitrogen atom within the heterocyclic backbone. Compounds having a 2-aza were 30- to 100-fold more potent than the 1-aza or the di-aza compounds against L1210 cells in vitro. When tested in vivo, the 2-aza-anthracenediones had marked anti-tumor activity, in some cases curative, whereas the 1-aza-anthracenediones had but minimal antitumor activity. To define the importance of the aza positioning on DNA reactivity, spectral shift and gel mobility assays were used. The spectral shift assay suggested that the 2-aza compounds reacted with DNA solely through intercalation whereas the 1-aza-anthracenediones, and mitoxantrone all reacted with DNA through intercalative and non-intercalative processes. The affinity of DNA binding was five to seven times greater for the 2-aza compounds compared to the 1-aza or the di-aza derivatives. The retardation of supercoiled pBR322 DNA mobility in agarose gel electrophoresis further suggested an intercalative type of DNA interaction. Differences in DNA interaction appear related to but can not completely account for differences in cytotoxicity of the aza anthracenediones.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750086     DOI: 10.1016/0304-3835(95)91035-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.

Authors:  Elias Péan; Beatriz Flores; Ian Hudson; Jan Sjöberg; Kristina Dunder; Tomas Salmonson; Christian Gisselbrecht; Edward Laane; Francesco Pignatti
Journal:  Oncologist       Date:  2013-04-24

2.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

3.  Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.

Authors:  B A P van Gorkom; H Timmer-Bosscha; S de Jong; D M van der Kolk; J H Kleibeuker; E G E de Vries
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

Review 4.  Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

Authors:  Stefano Volpetti; Francesco Zaja; Renato Fanin
Journal:  Onco Targets Ther       Date:  2014-05-29       Impact factor: 4.147

5.  CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.

Authors:  Benny J Evison; Rebecca A Bilardi; Francis C K Chiu; Gabriella Pezzoni; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2009-08-31       Impact factor: 16.971

6.  Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.

Authors:  Ben J Evison; Oula C Mansour; Ernesto Menta; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2007-05-05       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.